Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
3,621 total articles
Timothy R. White, President of Graco's Expansion Division, exercised options to buy 1,469 shares at $23.85 and sold 1,469 shares on February 4, 2026, at prices between $90.69 and $90.71 for proceeds of $133,233. A Form 4 filing details the transactions and White's remaining direct and indirect holdings. The disclosure comes amid Graco's fourth-quar…
Mark N. Tompkins, previously a 10% owner of Aeluma, Inc. (ALMU), sold $507,653 worth of common stock in two tranches on February 4, 2026. The trades occurred at prices between $13.94 and $15.50. The stock is trading below those sale levels and faces an upcoming earnings release on February 11. Recent company results showed a modest non-GAAP loss an…
Kathryn L. Schoenrock, Executive Vice President and Chief Information Officer of Graco Inc (NYSE: GGG), sold 2,223 shares on February 2, 2026, for $195,759 and exercised options for 3,336 shares the same day. Graco reported fourth-quarter 2025 EPS of $0.77 and revenue of $593.2 million, slightly above expectations, with management citing acquisitio…
Graco Inc. director J. Kevin Gilligan carried out a same-day option exercise and share sale on February 3, 2026. Gilligan exercised options to acquire 12,870 shares, then sold those 12,870 shares at a weighted average price of $89.0676, generating roughly $1.15 million in proceeds. After the transactions he holds no shares directly but retains an i…
Allogene Therapeutics Executive Vice President of Research and Development Zachary Roberts sold 35,700 shares on Feb. 2, 2026 for roughly $63,189, according to a Form 4 filing. The transaction occurred at prices between $1.71 and $1.87, close to the stock's cited trading level of $1.80. Roberts also received option awards and restricted stock units…
Jay D. Richards, an officer of a BankUnited subsidiary, sold 3,506 shares on February 3, 2026, for $49.83 per share, a transaction worth $174,703 executed under Rule 144. The sale leaves Richards with 35,687 shares. The move comes while BankUnited (BKU) trades near its 52-week high and follows a quarter that prompted multiple upward adjustments to …
John W. Kozarich, a director at Ligand Pharmaceuticals, sold 467 shares of the company on February 2, 2026, in transactions totaling $91,490. The trades were made under a pre-established Rule 10b5-1 plan adopted March 7, 2025. Ligand recently reported robust third-quarter revenue of $115.5 million, driven in part by $53.1 million from the Pelthos t…
Allogene Therapeutics President and CEO Chang David D. sold 95,269 shares on February 2, 2026 to meet tax withholding tied to vested restricted stock units, a transaction that generated $171,484. The move occurred against a backdrop of strong recent share performance, a favorable arbitration ruling on the company’s cell therapy, an earnings beat fo…
Fastly Chief Technology Officer Artur Bergman sold 20,000 Class A shares on February 2, 2026, for a weighted average price of $9.36, netting $187,200. The sale was executed under a Rule 10b5-1 trading plan adopted June 3, 2025. Separately, Fastly increased a convertible notes offering to $160 million, granted an option for up to $20 million more, a…
Zoom Communications CEO Eric S. Yuan sold $2.2 million of Class A shares across transactions on February 2 and 3 under a pre-arranged Rule 10b5-1 plan, while converting 24,200 Class B shares to Class A. The share sales spanned prices from $88.4963 to $93.821 per share. Separately, Zoom reported revenue growth of 4.4% year-over-year, outpacing UBS e…
Cavco Industries director Steven W. Moster bought 300 shares on February 2, 2026, at $456.23 per share for a total of $136,869. The transaction occurred after the stock declined roughly 18% over the prior week. Cavco reported Q3 FY2026 results that missed analyst expectations on both EPS and revenue, while the company is described as having more ca…
Bluescape Riley Exploration Holdings LLC and affiliated entities sold 230,334 shares of Riley Exploration Permian, Inc. (NASDAQ: REPX) common stock between February 2 and February 4, generating $6,571,913 in proceeds. The transactions occurred at prices between $28.0654 and $28.5625. Following the sales, Bluescape Riley Exploration Holdings LLC hol…
Warburg Pincus sold 11,849,999 shares of various Banc of California equity classes on February 2, 2026, at $20.00 per share, generating proceeds of $237,000,000. The transaction consisted of Voting Common, Non-Voting Common Equivalent and NVCE Stock. Banc of California’s recent fourth-quarter results outpaced analyst expectations, prompting several…
United Airlines Holdings President Brett J. Hart sold 19,000 shares on February 2, 2026, for $2.02 million and donated 5,695 shares to charity on February 3. The transaction leaves Hart with 264,638 directly held shares. The airline reported robust fourth-quarter 2025 results, prompting several price-target increases from major firms and plans to s…
Rush Street Interactive Chief Executive Officer Richard Todd Schwartz sold 247,114 shares of Class A common stock on February 4, 2026, in transactions executed under a pre-arranged 10b5-1 plan. The weighted average sale price was $17.6134, producing proceeds of $4,352,517. Following the trades, Schwartz directly holds 949,048 shares. Separately, Be…
Matthew David Feierstein, president of EverCommerce Inc. (NASDAQ:EVCM), completed a series of sales totaling 29,920 shares between February 2 and February 4, 2026, yielding $338,477. The transactions were executed under a Rule 10b5-1 plan established August 20, 2025. EverCommerce’s third-quarter 2025 revenue of $147.5 million slightly trailed analy…
Deanna H. Lund, executive vice president and chief financial officer of Kratos Defense & Security Solutions (KTOS), sold 4,990 shares on February 2, 2026, for about $484,362 under a 10b5-1 plan. The company has reported strong 12-month share gains and a very high P/E ratio, while advancing participation in the War Department's Drone Dominance Progr…
Cadence Design Systems Sr. Vice President Paul Cunningham sold 1,000 shares on February 2, 2026, for $295,090 under a pre-existing Rule 10b5-1 plan. The sale coincides with a recent pullback in the stock and precedes an upcoming earnings report; the company has also announced a new DSP product and a board appointment.
aTyr Pharma CEO Shukla Sanjay sold 3,745 shares on Feb. 4, 2026 to satisfy tax withholding associated with vested restricted stock units, after receiving 10,375 shares on Feb. 3, 2026. The company, with a market capitalization of $86.28 million, is trading slightly below its fair value while reporting that it holds more cash than debt but is rapidl…
Todd Watanabe, President and CEO of Arcutis Biotherapeutics (NASDAQ: ARQT), sold 19,833 shares on February 2, 2026, for $505,709 to satisfy tax withholding tied to restricted stock units. The transaction leaves Watanabe with 721,306 directly held shares and several additional holdings held indirectly through trusts and an LLC. The company has poste…
UroGen Pharma Ltd's Chief Medical Officer, Mark Schoenberg, sold 7,373 ordinary shares on February 3, 2026, at $19.69 apiece to satisfy withholding tax tied to settled restricted stock units. The company recently reported third-quarter 2025 results that missed consensus on earnings per share and revenue, and no analyst actions or M&A updates have b…
Adaptive Biotechnologies Chief Executive and Chairman Chad M. Robins sold 124,998 shares on February 2, 2026, for about $2.3 million under a Rule 10b5-1 plan. The transaction coincides with a year of notable revenue gains for the company and strategic agreements with Pfizer, though valuation metrics and negative EBITDA highlight ongoing financial c…
Director Peter A. Thompson reported the sale of Sionna Therapeutics stock across two days in early February 2026, totaling $1.37 million. The transactions occurred at prices between $44.57 and $44.58 per share. The company has recently drawn contrasting analyst views: Raymond James has raised its price target and kept a Strong Buy, while RBC Capita…
Adaptive Biotechnologies Chief Scientific Officer Harlan S. Robins sold 42,788 shares across February 2 and 3, 2026, realizing approximately $799,104. The transactions were carried out under a Rule 10b5-1 plan and occurred as the company reported significant 2025 revenue gains and announced strategic collaborations and financing activity.
Chief Financial Officer Daniella Beckman sold 10,317 shares of Tango Therapeutics (NASDAQ: TNGX) on February 3, 2026, realizing roughly $126,530. The disposals, reported on a Form 4 with the Securities and Exchange Commission, were executed in two transactions and were disclosed as tax-withholding sales tied to restricted stock unit vesting. The co…
